Akers Biosciences (NASDAQ:AKER) and Celldex Therapeutics (NASDAQ:CLDX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends and valuation.
Institutional and Insider Ownership
50.7% of Akers Biosciences shares are held by institutional investors. Comparatively, 27.8% of Celldex Therapeutics shares are held by institutional investors. 8.9% of Akers Biosciences shares are held by company insiders. Comparatively, 2.9% of Celldex Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
This table compares Akers Biosciences and Celldex Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility & Risk
Akers Biosciences has a beta of -0.93, meaning that its stock price is 193% less volatile than the S&P 500. Comparatively, Celldex Therapeutics has a beta of 2.69, meaning that its stock price is 169% more volatile than the S&P 500.
Valuation & Earnings
This table compares Akers Biosciences and Celldex Therapeutics’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Akers Biosciences||$3.93 million||4.25||-$7.36 million||N/A||N/A|
|Celldex Therapeutics||$12.74 million||3.52||-$93.03 million||($0.80)||-0.33|
Akers Biosciences has higher earnings, but lower revenue than Celldex Therapeutics.
This is a breakdown of recent ratings and target prices for Akers Biosciences and Celldex Therapeutics, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Celldex Therapeutics has a consensus price target of $2.67, suggesting a potential upside of 925.64%. Given Celldex Therapeutics’ higher possible upside, analysts plainly believe Celldex Therapeutics is more favorable than Akers Biosciences.
Celldex Therapeutics beats Akers Biosciences on 6 of the 11 factors compared between the two stocks.
Akers Biosciences Company Profile
Akers Biosciences, Inc., together with its subsidiaries, develops, manufactures, and supplies rapid screening and testing products designed to deliver healthcare information to healthcare providers and consumers in the United States, the People's Republic of China, and internationally. The company's marketed products include BreathScan, a disposable breath alcohol detector; BreathScan PRO, a quantitative breath alcohol detection system; METRON, a disposable breath ketone device to monitor ketosis; and BreathScan Lync, a non-invasive, quantitative measurement of biological markers for health and wellness. Its marketed products also include PIFA Heparin/PF4 and PIFA PLUSS PF4 rapid tests for Heparin/PF4 antibodies to detect an allergy to the used blood thinner, Heparin; seraSTAT, a rapid blood cell separator; Tri-Cholesterol Check', a rapid test for total and high density lipoprotein cholesterol and estimates low density lipo protein; and BreathScan OxiCHek, a breath test for oxidative stress using the Lync reader and digital app. The company's pipeline products comprise Breath Diabetic Ketoacidosis, a disposable breath ketone device for diabetic monitoring; Breath PulmoHealth Check', a suite of breath tests for biomarkers indicating asthma, chronic obstructive pulmonary disease, and lung cancer; PIFA PLUSS Chlamydia, a rapid test for sexually transmitted diseases; and BreathScan KetoChek, a breath test for ketosis using the Lync reader and digital app. Akers Biosciences, Inc. was founded in 1989 and is headquartered in Thorofare, New Jersey.
Celldex Therapeutics Company Profile
Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of various immunotherapy technologies and other cancer-targeting biologics. Its drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer; and CDX-3379, a human monoclonal antibody that is in Phase II study in combination with cetuximab for the treatment of head and neck squamous cell carcinoma. The company also develops earlier stage drug candidates that are in clinical development, including CDX-014, an antibody-drug conjugate targeting renal and ovarian cancers; CDX-1140, a human monoclonal antibody; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-1401, an immunotherapeutic aimed at antigen presenting cells for cancer indications. Celldex Therapeutics, Inc. has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; University of Southampton; Amgen Inc.; Amgen Fremont; Seattle Genetics, Inc.; Yale University; and MedImmune, LLC. The company is headquartered in Hampton, New Jersey.
Receive News & Ratings for Akers Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akers Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.